ClinicalTrials.gg
RecruitingNCT05489952Updated Sep 22, 2022

Iron Supplementation for Geriatric Hip Fractures

A Phase 4 interventional study of iron sucrose and ferrous lactate in Hip Fractures, Fragility Fracture and Osteoporotic Fractures, sponsored by He Qifei. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2022-09-22.

Sponsored by He Qifei · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Hip Fractures with a site in China — 15 open to participants now, 16 under way, none of them phase 3. Hip Fractures · China.

Planned enrollment
7th of 34
444 · median 110
Started
2022
with 5 others
Phase 4
5 of 51
2 open now
Primary completion
2025-02
later than 0 of 15 live
Registered
27th of 51
by date

Among the 51 studies in Hip Fractures with a site in China, this one is the 7th largest by planned enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2022, is one of 5 in phase 4, reaches primary completion later than 0 of the 15 other live ones, and was the 27th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

15 of the 51 studies in Hip Fractures with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hip Fractures with a site in China, or all of them as a file.
02

Study summary

Geriatric hip fracture is an important disease that affects the health life of the elderly in China. Geriatric hip fracture is often complicated by a variety of comorbidities due to advanced age. And anemia is a common comorbidity. At present perioperative management of geriatric hip fracture, transfusion is only indicated for moderate and severe anemia, while no special medical intervention for mild anemia in China. More and more studies have found that iron can not only correct anemia, but also improve cardiac function, patients' quality of life and function. This study investigated the effect of perioperative iron supplementation on activity tolerance in elderly patients with hip fracture complicated with iron deficiency anemia. The study was a randomized, parallel controlled clinical study. Due to the requirements of the ethics committee, the unblinded setting was cancelled due to ethical considerations. Research will be grouped according to whether to accept iron supplementation treatment, are divided into 2 groups, respectively, iron treatment group and the traditional method. The method of randomization was stratified block randomization. The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge. The outcomes include 6-minute walk distance, Harris score, EQ-5D score six months after surgery, perioperative blood transfusion rate, and so on in the two groups.

03

Conditions studied

  • Hip Fractures
  • Fragility Fracture
  • Osteoporotic Fractures
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. >65 years old patients with hip fracture
  2. Patients with iron deficiency or anemia,

    • preoperative \<13g/ dL in males and \<12g/ dL in females, and >9g/ dL,
    • serum ferritin \< 100 ng/ mL or serum ferritin 100-299 ng/ mL or transferrin saturation (TSAT) \<20%

Exclusion criteria

Exclusion Criteria:

  1. Coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, and cardiac device implantation (including cardiac resynchronization) within preoperative 30 days
  2. Acute coronary syndrome, or stroke occurred within 30 days before surgery;
  3. Refused to sign the consent form to be included in the clinical trial group;
  4. Can't walk before injury;
  5. Use erythropoietic preparation within 3 months before surgery and oral iron preparation within 4 weeks 30 days before surgery(> 100 mg/ day)
  6. Patients with liver and kidney dysfunction
  7. Other conditions that the researchers considered inappropriate for inclusion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
444 participants (estimated)

Study arms

  • Experimental
    iron supplement group

    Drug: iron sucrose and ferrous lactate

  • No intervention
    control group

Interventions

  • Drugiron sucrose and ferrous lactate

    Drug page: Iron sucroseStudies of Iron sucroseIron sucrose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.

    Also known as: iron supplementation

06

What researchers measure

Primary outcomes

  1. 6-minute walk distance

    The 6-minute walk distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise. The 6 MWT provides information regarding functional capacity, response to therapy and prognosis across a broad range of chronic cardiopulmonary conditions.

    Time frame: 6 months

Secondary outcomes

  1. Harris hip score

    The Harris Hip Scale (HHS) was developed for the assessment of the results of hip surgery, and is intended to evaluate various hip disabilities and methods of treatment in an adult population.

    Time frame: 6 months

  2. perioperative blood transfusion rate

    The proportion of the transfusions number to the total number of patients

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
  • Shenzhen Second People's Hospita
    Shenzhen, Guangdong 518035, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2022; primary completion for Feb 2025, 29 months later.

Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 29 months is above that.

Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2022
First posted
Aug 5, 2022
StartEst.
Sep 15, 2022
Primary completionEst.
Feb 15, 2025
CompletionEst.
Aug 15, 2025
Last update
Sep 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05489952
Lead sponsor
He Qifei
Responsible party
He Qifei (Principal Investigator, Shenzhen Second People's Hospital) — Sponsor-investigator
First posted
Aug 5, 2022
Start date
Sep 15, 2022 (estimated)
Primary completion
Feb 15, 2025 (estimated)
Completion
Aug 15, 2025 (estimated)
Last update
Sep 22, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron sucrose

Start the discussion